Premium
Response to Denosumab Treatment for 2 Years in an Adolescent With Osteoradionecrosis
Author(s) -
Vázquez M Angeles,
PérezTemprano Ramón,
Montoya M José,
Giner Mercè,
Carpio José,
PérezCano Ramon
Publication year - 2015
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.2519
Subject(s) - osteoradionecrosis , denosumab , medicine , bone density conservation agents , surgery , osteoporosis , radiation therapy , bone density
Radiotherapy, an essential component of cancer treatment, is not without risk to bone, particularly to the immature or growing skeleton. Known side effects range from post‐radiation osteitis to osteoradionecrosis. We report the case of a 14‐year‐old male patient undergoing denosumab treatment, a new antiresorptive agent, for osteoradionecrosis. The patient exhibited fractures and associated pain and functional limitations secondary to radiation for the treatment of an embryonal rhabdomyosarcoma of prostate grade III administered at age 5 years. After treatment with denosumab, the pain disappeared, bone remodeling markers dramatically declined, bone mass increased, and pathological bone scan findings resolved without adverse effects or new fractures. © 2015 American Society for Bone and Mineral Research.